Patient and health facility attributes associated with retention and virologic suppression in private for-profit health facilities in Nigeria.
AIDS
HIV
Implementation science
Nigeria
Patient outcomes
Private facilities
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
22 02 2022
22 02 2022
Historique:
received:
06
09
2021
accepted:
07
02
2022
entrez:
23
2
2022
pubmed:
24
2
2022
medline:
3
5
2022
Statut:
epublish
Résumé
In Nigeria, private for-profit health facilities present an opportunity to achieve the UNAIDS 95-95-95 HIV targets because of their reach and patronage. However, little is known about determinants of outcomes in these facilities. This study describes patient outcomes and the patient and health facility characteristics associated with these outcomes in adults receiving HIV treatment in private facilities in the Federal Capital Territory (FCT), Benue and Nasarawa states in north-central Nigeria. A retrospective longitudinal analysis of program data collected between 2013 and 2019 was done. Patient attributes and outcomes were compared across the two states and FCT. Incidence rates were determined for all cause exit, mortality and loss to follow up (LTFU). Cox proportional hazard models were used to identify associations between patient and facility attributes and these outcomes. Bivariate and multivariate logistic regression models were used to determine the factors associated with viral suppression among the study participants. Of the 22,010 study subjects, 42.7%, 22.2% and 35.1%, respectively, were in Benue, FCT and Nasarawa. Almost a third (31.8%) had received antiretroviral treatment (ART) for less than a year at censoring. Incidence rates for all-cause exit, mortality and loss to follow up (LTFU) were 17.2 (95% CI 16.8, 17.5), 2.1 (95% CI 2.0, 2.2), and 11.2 (95% CI 10.8, 11.8) per 100 person years respectively. Males had higher risks of death (HR = 1.47, 95% CI 1.25-1.73), and LTFU (HR = 1.08, 95% CI 1.00-1.16). Age at ART start showed a dose-response association with both mortality and LTFU. Care at model facilities (OR = 2.16, p < 0.001), Zidovudine (AZT)-based regimens (OR = 2.00, p < 0.001), and lowest quartile baseline CD4 + count (OR = 2.40, p < 0.001) were associated with regimen switch. 75.6% of subjects were viral suppressed. Male gender (OR = 0.84, p = 0.025); AZT-based regimen (OR = 0.72, p < 0.001), age in the bottom quartile (OR = 0.71, p = 0.002) were associated with virally suppression. Private for-profit facilities are a major provider of HIV and other health services in Nigeria. With appropriate technical support and engagement, they can help accelerate efforts to achieve epidemic control of HIV in Nigeria, and contribute to achievement of UNAIDS 95-95-95 target by 2030.
Sections du résumé
BACKGROUND
In Nigeria, private for-profit health facilities present an opportunity to achieve the UNAIDS 95-95-95 HIV targets because of their reach and patronage. However, little is known about determinants of outcomes in these facilities. This study describes patient outcomes and the patient and health facility characteristics associated with these outcomes in adults receiving HIV treatment in private facilities in the Federal Capital Territory (FCT), Benue and Nasarawa states in north-central Nigeria.
METHODS
A retrospective longitudinal analysis of program data collected between 2013 and 2019 was done. Patient attributes and outcomes were compared across the two states and FCT. Incidence rates were determined for all cause exit, mortality and loss to follow up (LTFU). Cox proportional hazard models were used to identify associations between patient and facility attributes and these outcomes. Bivariate and multivariate logistic regression models were used to determine the factors associated with viral suppression among the study participants.
RESULTS
Of the 22,010 study subjects, 42.7%, 22.2% and 35.1%, respectively, were in Benue, FCT and Nasarawa. Almost a third (31.8%) had received antiretroviral treatment (ART) for less than a year at censoring. Incidence rates for all-cause exit, mortality and loss to follow up (LTFU) were 17.2 (95% CI 16.8, 17.5), 2.1 (95% CI 2.0, 2.2), and 11.2 (95% CI 10.8, 11.8) per 100 person years respectively. Males had higher risks of death (HR = 1.47, 95% CI 1.25-1.73), and LTFU (HR = 1.08, 95% CI 1.00-1.16). Age at ART start showed a dose-response association with both mortality and LTFU. Care at model facilities (OR = 2.16, p < 0.001), Zidovudine (AZT)-based regimens (OR = 2.00, p < 0.001), and lowest quartile baseline CD4 + count (OR = 2.40, p < 0.001) were associated with regimen switch. 75.6% of subjects were viral suppressed. Male gender (OR = 0.84, p = 0.025); AZT-based regimen (OR = 0.72, p < 0.001), age in the bottom quartile (OR = 0.71, p = 0.002) were associated with virally suppression.
CONCLUSION
Private for-profit facilities are a major provider of HIV and other health services in Nigeria. With appropriate technical support and engagement, they can help accelerate efforts to achieve epidemic control of HIV in Nigeria, and contribute to achievement of UNAIDS 95-95-95 target by 2030.
Identifiants
pubmed: 35193597
doi: 10.1186/s12981-022-00438-3
pii: 10.1186/s12981-022-00438-3
pmc: PMC8864871
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Zidovudine
4B9XT59T7S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2017 Nov 14;12(11):e0185348
pubmed: 29136011
Int J Health Policy Manag. 2013 Dec 09;2(1):13-9
pubmed: 24596895
BMC Infect Dis. 2015 Nov 14;15:517
pubmed: 26572102
BMJ Open. 2015 May 22;5(5):e007508
pubmed: 26002691
BMC Res Notes. 2013 Dec 05;6:512
pubmed: 24308609
Public Health Rep. 2010 Jul-Aug;125 Suppl 4:16-24
pubmed: 20629252
PLoS One. 2018 Jan 30;13(1):e0192077
pubmed: 29381736
Glob Health Action. 2013 Dec 13;6:22571
pubmed: 24331715
Lancet. 2005 Aug 20-26;366(9486):676-81
pubmed: 16112305
Int J Equity Health. 2007 Nov 07;6:17
pubmed: 17988396
AIDS Res Ther. 2019 Oct 8;16(1):30
pubmed: 31594539
Health Policy Plan. 2014 Jul;29 Suppl 1:i1-3
pubmed: 25012793
J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):102-10
pubmed: 26761273
AIDS Res Treat. 2014;2014:560623
pubmed: 25028610
J Int AIDS Soc. 2016 Jul 15;19(1):21133
pubmed: 27424601
Health Policy Plan. 2011 Jul;26 Suppl 1:i72-84
pubmed: 21729920
BMC Int Health Hum Rights. 2011 Mar 09;11 Suppl 1:S9
pubmed: 21411009
Bull World Health Organ. 2002;80(4):325-30
pubmed: 12075370
AIDS. 2003;17 Suppl 4:S3-11
pubmed: 15080170
AIDS Res Hum Retroviruses. 2014 Jun;30(6):531-4
pubmed: 24803320
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):314-20
pubmed: 22343178
AIDS Res Ther. 2017 Feb 1;14(1):5
pubmed: 28143541
PLoS One. 2016 Nov 9;11(11):e0165528
pubmed: 27829033
BMC Public Health. 2013 Jan 15;13:38
pubmed: 23320567